News

Epigenomics’ diagnostic test is being developed as an aid in diagnosis for lung cancer and may help pathologists to confirm the diagnosis of malignant lung disease when current

Under the terms of the agreement, Basilea will receive an upfront payment of CHF75m and will be eligible to receive up to CHF478m in additional payments on achievement

Developed based on MedNet’s extensive, decade-long experience supporting world-wide clinical trials and registries, iMedNet is a Web 2.0-based EDC solution built using advanced technology tools available. MedNet claimed

LIPO-102 is a new, minimally-invasive, non-ablative approach to localised fat reduction comprising an injectable aqueous combination of salmeterol xinafoate (SX) and fluticasone propionate (FP). Injection of LIPO-102 is

The company has also reported that the USPTO has issued US Patent No 7666415, covering bispecific antibody constructs incorporating the company’s proprietary histamine-succinyl-glycine (HSG)-binding 679 antibody. Cynthia Sullivan,

AVAGAST is a multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate Avastin plus Xeloda (capecitabine) or 5-FU and cisplatin chemotherapy compared to Xeloda or 5-FU and

The three-year award totaling approximately $3m will support collaborative research by investigators at Sanaria and Columbia University. The new funding extends previous NIAID supported efforts at Sanaria and

The FDA approved Bioguard is a non-leaching antimicrobial dressing and had its first commercial sale of the product in June 2009. The dressings serve as a barrier to

However, FDA has added information to the Specific Populations section of the product label under ‘Heart Failure’ stating that in a placebo-controlled trial of 2,128 patients (1,067 with